PDEX Quote, Financials, Valuation and Earnings

Picard Medical has a net margin of 25.26% compared to Pro-Dex, Inc.'s net margin of --. Pro-Dex, Inc.'s return on equity of 31.77% beat Picard Medical's return on equity of --.

Pro-Dex, Inc. has a consensus price target of $56.00, signalling upside risk potential of 36.59%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Pro-Dex, Inc. has higher upside potential than Picard Medical, analysts believe Pro-Dex, Inc. is more attractive than Picard Medical.

Pro-Dex, Inc. has a beta of -0.090, which suggesting that the stock is 109.027% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pro-Dex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.

Pro-Dex, Inc. quarterly revenues are $18.5M, which are larger than Picard Medical quarterly revenues of --. Pro-Dex, Inc.'s net income of $4.7M is higher than Picard Medical's net income of --. Notably, Pro-Dex, Inc.'s price-to-earnings ratio is 12.23x while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex, Inc. is 1.95x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 25.26% compared to Pro-Dex, Inc.'s net margin of -862.39%. Pro-Dex, Inc.'s return on equity of 31.77% beat VolitionRX Ltd.'s return on equity of --.

Pro-Dex, Inc. has a consensus price target of $56.00, signalling upside risk potential of 36.59%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 773.95%. Given that VolitionRX Ltd. has higher upside potential than Pro-Dex, Inc., analysts believe VolitionRX Ltd. is more attractive than Pro-Dex, Inc..

Pro-Dex, Inc. has a beta of -0.090, which suggesting that the stock is 109.027% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Pro-Dex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Pro-Dex, Inc. quarterly revenues are $18.5M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Pro-Dex, Inc.'s net income of $4.7M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Pro-Dex, Inc.'s price-to-earnings ratio is 12.23x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex, Inc. is 1.95x versus 20.39x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of 25.26% compared to Pro-Dex, Inc.'s net margin of -1037.17%. Pro-Dex, Inc.'s return on equity of 31.77% beat Catheter Precision, Inc.'s return on equity of -192.05%.

Pro-Dex, Inc. has a consensus price target of $56.00, signalling upside risk potential of 36.59%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1188.17%. Given that Catheter Precision, Inc. has higher upside potential than Pro-Dex, Inc., analysts believe Catheter Precision, Inc. is more attractive than Pro-Dex, Inc..

Pro-Dex, Inc. has a beta of -0.090, which suggesting that the stock is 109.027% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

Pro-Dex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

Pro-Dex, Inc. quarterly revenues are $18.5M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Pro-Dex, Inc.'s net income of $4.7M is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Pro-Dex, Inc.'s price-to-earnings ratio is 12.23x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex, Inc. is 1.95x versus 13.87x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 25.26% compared to Pro-Dex, Inc.'s net margin of 3.93%. Pro-Dex, Inc.'s return on equity of 31.77% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Pro-Dex, Inc. has a consensus price target of $56.00, signalling upside risk potential of 36.59%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 111.92%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Pro-Dex, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Pro-Dex, Inc..

Pro-Dex, Inc. has a beta of -0.090, which suggesting that the stock is 109.027% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Pro-Dex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Pro-Dex, Inc. quarterly revenues are $18.5M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Pro-Dex, Inc.'s net income of $4.7M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Pro-Dex, Inc.'s price-to-earnings ratio is 12.23x while Xtant Medical Holdings, Inc.'s PE ratio is 69.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex, Inc. is 1.95x versus 0.77x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.